Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 2015

View Archived Issues

Bcl-2-like protein 11 is directly involved in beta cell apoptosis

TALENs used to disrupt gene for Rhesus D antigen in erythroid progenitor cells

Afferent Pharmaceuticals reports results from phase IIb trial of AF-219 in chronic cough

MPS1 inhibitor S-81694 begins first-in-human study for solid tumors

Advaxis initiates phase I study of ADXS-HER2 for HER2-expressing solid tumors

Aduro Biotech to acquire BioNovion

MedImmune and 3M Drug Delivery Systems collaborate to develop next-generation TLR agonists

Intercept Pharmaceuticals starts phase III trial of obeticholic acid in NASH with fibrosis

Verona releases data on new suspension formulation of RPL-554 in patients with COPD

FDA confirms data needed for Medidur NDA filing

BioMarin starts phase I/II trial of hemophilia A gene therapy BMN-270

Ablynx starts phase III trial of caplacizumab in acquired TTP

PDE4D is involved in Hedgehog signaling and could be targeted to treat medulloblastoma

CFTR gene therapy is associated with stabilization of lung function in phase IIb CF trial

F2G reports PK/PD profile of novel orotomide antifungal F-901318

IURTC and Assembly Biosciences patent HBV core protein allosteric modulators

Department of Health of the U.K. and JNCASR describe antimicrobial conjugates

Principia Biopharma reports TXK and ITK inhibitors

Merck & Co. and Merck Frosst Canada report HIV protease inhibitors

Takeda submits NDA for fixed-dose combination of Nesina and metformin in Japan

Endo confirms termination of waiting period for Par Pharmaceutical acquisition

Circulating miRNA levels associated with insulin resistance in metabolic syndrome

Maruho's Zebiax approved in Japan for bacterial skin infections

Topline results from third phase III trial of baricitinib for rheumatoid arthritis

Promising outcome in phase III ORATORIO study of ocrelizumab in primary progressive MS

FDA and EMA accept filings for rociletinib for NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...